Effects of N-3 Fatty Acids on Decline of Kidney Function after Myocardial Infarction: Alpha Omega Trial

Ellen Hoogeveen, Eugenie Gemen, Marianne Geleijnse, Ron Kusters, Daan Kromhout, Erik Giltay

    Research output: Contribution to journalMeeting AbstractAcademic

    Abstract

    Introduction and Aims: Chronic kidney disease (CKD) is a major risk factor of cardiovascular disease and mortality in both the general population and post-myocardial patients. Kidney function gradually decreases with age (±1 ml/min/y), but in patients with a myocardial infarction (MI) this deterioration is accelerated (±2 ml/min/y). Epidemiological and experimental studies suggest that n-3 fatty acids supplementation may prevent or slow the decline of kidney function. We examined the effect of the marine n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic (DHA) and of the plant-derived alpha-linolenic acid (ALA) on the decline of kidney function among patients who have had a first myocardial infaction.

    Methods: In a secondary analysis of the randomized, double blind, placebo-controlled Alpha Omega Trial, 2426 of 4937 (49%) patients (aged 60-80y; 79% men) were included of whom kidney function was measured both at baseline and at 41 months of follow-up. Margarine spreads were used to deliver 400 mg EPA-DHA/d, 2g ALA/d, both EPA-DHA and ALA, or a placebo for 40 months. We measured at baseline and end of follow-up both serum creatinine and Cystatin-C and calculated the estimated GFR (eGFR) from the CKD Epidemiology Collaboration (CKD-EPI) equations. Baseline characteristics were compared among the four treatment groups using ANOVA. The decline of kidney function in the three treatment groups ALA, EPA-DHA and EPA-DHA plus ALA were compared to the placebo group.

    Results: The 4 randomly assigned groups did not differ in baseline characteristics. Supplementation of ALA, EPA-DHA, EPA and DHA increased plasma cholesteryl ester concentrations of ALA, EPA, and DHA. At baseline kidney function did not differ between the four groups, mean (SD) creatinine and cystatin-C based eGFR were 76 (20) ml/min/1.73m2 and 80 (19) ml/min/1.73m2, respectively. During 41 months of follow-up the yearly decline of creatinine and cystatin-C based eGFR (SE) were in the placebo group (background): -2.28 (SE 0.20) and -1.31 (SE 0.12) ml/min/1.73m2/y, respectively. In comparison to the placebo group the mean difference (SE) of the yearly decline of creatinine and cystatine-C based eGFR (SE) were in the ALA supplementation group 0.05 (SE 0.28, P=0.86) and 0.23 (SE 0.18, P=0.20), in the EPA-DHA group 0.56 (SE 0.29, P=0.058) and 0.33 (SE 0.18, P=0.060) and in the EPA-DHA plus ALA group 0.24 (SE 0.29, P=0.40) and 0.28 (SE 0.18, P=0.10; Figure 1). Decline of kidney function (with error bars indicating SE) after 41 months, according to study group. P-value by three independent samples t-tests compared to the placebo group.

    Conclusions: In patients who had experienced a MI, low-dose supplementation with n-3 fatty acids did not statistically significantly reduce the decline in kidney function. However, there was a trend for EPA-DHA supplementation to slow down the decline of kidney function. These results should be confirmed in a study supplementing with higher doses of n-3 fatty acids.
    Original languageEnglish
    Pages (from-to)ii64-ii64
    JournalNephrology Dialysis Transplantation
    Volume27
    Issue numberSuppl. 2
    DOIs
    Publication statusPublished - May 2012

    Cite this

    Hoogeveen, Ellen ; Gemen, Eugenie ; Geleijnse, Marianne ; Kusters, Ron ; Kromhout, Daan ; Giltay, Erik. / Effects of N-3 Fatty Acids on Decline of Kidney Function after Myocardial Infarction : Alpha Omega Trial. In: Nephrology Dialysis Transplantation. 2012 ; Vol. 27, No. Suppl. 2. pp. ii64-ii64.
    @article{2d556164e5584d209cbfe50434f2ce0c,
    title = "Effects of N-3 Fatty Acids on Decline of Kidney Function after Myocardial Infarction: Alpha Omega Trial",
    abstract = "Introduction and Aims: Chronic kidney disease (CKD) is a major risk factor of cardiovascular disease and mortality in both the general population and post-myocardial patients. Kidney function gradually decreases with age (±1 ml/min/y), but in patients with a myocardial infarction (MI) this deterioration is accelerated (±2 ml/min/y). Epidemiological and experimental studies suggest that n-3 fatty acids supplementation may prevent or slow the decline of kidney function. We examined the effect of the marine n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic (DHA) and of the plant-derived alpha-linolenic acid (ALA) on the decline of kidney function among patients who have had a first myocardial infaction.Methods: In a secondary analysis of the randomized, double blind, placebo-controlled Alpha Omega Trial, 2426 of 4937 (49{\%}) patients (aged 60-80y; 79{\%} men) were included of whom kidney function was measured both at baseline and at 41 months of follow-up. Margarine spreads were used to deliver 400 mg EPA-DHA/d, 2g ALA/d, both EPA-DHA and ALA, or a placebo for 40 months. We measured at baseline and end of follow-up both serum creatinine and Cystatin-C and calculated the estimated GFR (eGFR) from the CKD Epidemiology Collaboration (CKD-EPI) equations. Baseline characteristics were compared among the four treatment groups using ANOVA. The decline of kidney function in the three treatment groups ALA, EPA-DHA and EPA-DHA plus ALA were compared to the placebo group.Results: The 4 randomly assigned groups did not differ in baseline characteristics. Supplementation of ALA, EPA-DHA, EPA and DHA increased plasma cholesteryl ester concentrations of ALA, EPA, and DHA. At baseline kidney function did not differ between the four groups, mean (SD) creatinine and cystatin-C based eGFR were 76 (20) ml/min/1.73m2 and 80 (19) ml/min/1.73m2, respectively. During 41 months of follow-up the yearly decline of creatinine and cystatin-C based eGFR (SE) were in the placebo group (background): -2.28 (SE 0.20) and -1.31 (SE 0.12) ml/min/1.73m2/y, respectively. In comparison to the placebo group the mean difference (SE) of the yearly decline of creatinine and cystatine-C based eGFR (SE) were in the ALA supplementation group 0.05 (SE 0.28, P=0.86) and 0.23 (SE 0.18, P=0.20), in the EPA-DHA group 0.56 (SE 0.29, P=0.058) and 0.33 (SE 0.18, P=0.060) and in the EPA-DHA plus ALA group 0.24 (SE 0.29, P=0.40) and 0.28 (SE 0.18, P=0.10; Figure 1). Decline of kidney function (with error bars indicating SE) after 41 months, according to study group. P-value by three independent samples t-tests compared to the placebo group.Conclusions: In patients who had experienced a MI, low-dose supplementation with n-3 fatty acids did not statistically significantly reduce the decline in kidney function. However, there was a trend for EPA-DHA supplementation to slow down the decline of kidney function. These results should be confirmed in a study supplementing with higher doses of n-3 fatty acids.",
    author = "Ellen Hoogeveen and Eugenie Gemen and Marianne Geleijnse and Ron Kusters and Daan Kromhout and Erik Giltay",
    year = "2012",
    month = "5",
    doi = "10.1093/ndt/gfs206",
    language = "English",
    volume = "27",
    pages = "ii64--ii64",
    journal = "Nephrology Dialysis Transplantation",
    issn = "0931-0509",
    publisher = "Oxford University Press",
    number = "Suppl. 2",

    }

    Effects of N-3 Fatty Acids on Decline of Kidney Function after Myocardial Infarction : Alpha Omega Trial. / Hoogeveen, Ellen; Gemen, Eugenie; Geleijnse, Marianne; Kusters, Ron; Kromhout, Daan; Giltay, Erik.

    In: Nephrology Dialysis Transplantation, Vol. 27, No. Suppl. 2, 05.2012, p. ii64-ii64.

    Research output: Contribution to journalMeeting AbstractAcademic

    TY - JOUR

    T1 - Effects of N-3 Fatty Acids on Decline of Kidney Function after Myocardial Infarction

    T2 - Alpha Omega Trial

    AU - Hoogeveen, Ellen

    AU - Gemen, Eugenie

    AU - Geleijnse, Marianne

    AU - Kusters, Ron

    AU - Kromhout, Daan

    AU - Giltay, Erik

    PY - 2012/5

    Y1 - 2012/5

    N2 - Introduction and Aims: Chronic kidney disease (CKD) is a major risk factor of cardiovascular disease and mortality in both the general population and post-myocardial patients. Kidney function gradually decreases with age (±1 ml/min/y), but in patients with a myocardial infarction (MI) this deterioration is accelerated (±2 ml/min/y). Epidemiological and experimental studies suggest that n-3 fatty acids supplementation may prevent or slow the decline of kidney function. We examined the effect of the marine n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic (DHA) and of the plant-derived alpha-linolenic acid (ALA) on the decline of kidney function among patients who have had a first myocardial infaction.Methods: In a secondary analysis of the randomized, double blind, placebo-controlled Alpha Omega Trial, 2426 of 4937 (49%) patients (aged 60-80y; 79% men) were included of whom kidney function was measured both at baseline and at 41 months of follow-up. Margarine spreads were used to deliver 400 mg EPA-DHA/d, 2g ALA/d, both EPA-DHA and ALA, or a placebo for 40 months. We measured at baseline and end of follow-up both serum creatinine and Cystatin-C and calculated the estimated GFR (eGFR) from the CKD Epidemiology Collaboration (CKD-EPI) equations. Baseline characteristics were compared among the four treatment groups using ANOVA. The decline of kidney function in the three treatment groups ALA, EPA-DHA and EPA-DHA plus ALA were compared to the placebo group.Results: The 4 randomly assigned groups did not differ in baseline characteristics. Supplementation of ALA, EPA-DHA, EPA and DHA increased plasma cholesteryl ester concentrations of ALA, EPA, and DHA. At baseline kidney function did not differ between the four groups, mean (SD) creatinine and cystatin-C based eGFR were 76 (20) ml/min/1.73m2 and 80 (19) ml/min/1.73m2, respectively. During 41 months of follow-up the yearly decline of creatinine and cystatin-C based eGFR (SE) were in the placebo group (background): -2.28 (SE 0.20) and -1.31 (SE 0.12) ml/min/1.73m2/y, respectively. In comparison to the placebo group the mean difference (SE) of the yearly decline of creatinine and cystatine-C based eGFR (SE) were in the ALA supplementation group 0.05 (SE 0.28, P=0.86) and 0.23 (SE 0.18, P=0.20), in the EPA-DHA group 0.56 (SE 0.29, P=0.058) and 0.33 (SE 0.18, P=0.060) and in the EPA-DHA plus ALA group 0.24 (SE 0.29, P=0.40) and 0.28 (SE 0.18, P=0.10; Figure 1). Decline of kidney function (with error bars indicating SE) after 41 months, according to study group. P-value by three independent samples t-tests compared to the placebo group.Conclusions: In patients who had experienced a MI, low-dose supplementation with n-3 fatty acids did not statistically significantly reduce the decline in kidney function. However, there was a trend for EPA-DHA supplementation to slow down the decline of kidney function. These results should be confirmed in a study supplementing with higher doses of n-3 fatty acids.

    AB - Introduction and Aims: Chronic kidney disease (CKD) is a major risk factor of cardiovascular disease and mortality in both the general population and post-myocardial patients. Kidney function gradually decreases with age (±1 ml/min/y), but in patients with a myocardial infarction (MI) this deterioration is accelerated (±2 ml/min/y). Epidemiological and experimental studies suggest that n-3 fatty acids supplementation may prevent or slow the decline of kidney function. We examined the effect of the marine n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic (DHA) and of the plant-derived alpha-linolenic acid (ALA) on the decline of kidney function among patients who have had a first myocardial infaction.Methods: In a secondary analysis of the randomized, double blind, placebo-controlled Alpha Omega Trial, 2426 of 4937 (49%) patients (aged 60-80y; 79% men) were included of whom kidney function was measured both at baseline and at 41 months of follow-up. Margarine spreads were used to deliver 400 mg EPA-DHA/d, 2g ALA/d, both EPA-DHA and ALA, or a placebo for 40 months. We measured at baseline and end of follow-up both serum creatinine and Cystatin-C and calculated the estimated GFR (eGFR) from the CKD Epidemiology Collaboration (CKD-EPI) equations. Baseline characteristics were compared among the four treatment groups using ANOVA. The decline of kidney function in the three treatment groups ALA, EPA-DHA and EPA-DHA plus ALA were compared to the placebo group.Results: The 4 randomly assigned groups did not differ in baseline characteristics. Supplementation of ALA, EPA-DHA, EPA and DHA increased plasma cholesteryl ester concentrations of ALA, EPA, and DHA. At baseline kidney function did not differ between the four groups, mean (SD) creatinine and cystatin-C based eGFR were 76 (20) ml/min/1.73m2 and 80 (19) ml/min/1.73m2, respectively. During 41 months of follow-up the yearly decline of creatinine and cystatin-C based eGFR (SE) were in the placebo group (background): -2.28 (SE 0.20) and -1.31 (SE 0.12) ml/min/1.73m2/y, respectively. In comparison to the placebo group the mean difference (SE) of the yearly decline of creatinine and cystatine-C based eGFR (SE) were in the ALA supplementation group 0.05 (SE 0.28, P=0.86) and 0.23 (SE 0.18, P=0.20), in the EPA-DHA group 0.56 (SE 0.29, P=0.058) and 0.33 (SE 0.18, P=0.060) and in the EPA-DHA plus ALA group 0.24 (SE 0.29, P=0.40) and 0.28 (SE 0.18, P=0.10; Figure 1). Decline of kidney function (with error bars indicating SE) after 41 months, according to study group. P-value by three independent samples t-tests compared to the placebo group.Conclusions: In patients who had experienced a MI, low-dose supplementation with n-3 fatty acids did not statistically significantly reduce the decline in kidney function. However, there was a trend for EPA-DHA supplementation to slow down the decline of kidney function. These results should be confirmed in a study supplementing with higher doses of n-3 fatty acids.

    U2 - 10.1093/ndt/gfs206

    DO - 10.1093/ndt/gfs206

    M3 - Meeting Abstract

    VL - 27

    SP - ii64-ii64

    JO - Nephrology Dialysis Transplantation

    JF - Nephrology Dialysis Transplantation

    SN - 0931-0509

    IS - Suppl. 2

    ER -